Dyne Therapeutics has patented a method for reducing DMPK expression in muscle cells by administering a complex with an anti-transferrin receptor antibody linked to an oligonucleotide targeting DMPK RNA. The oligonucleotide degrades DMPK RNA via RNase H mediated degradation, offering a potential treatment for diseases associated with DMPK alleles. GlobalData’s report on Dyne Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Dyne Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Dyne Therapeutics, Antibody-conjugate nanoparticles was a key innovation area identified from patents. Dyne Therapeutics's grant share as of February 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for method of reducing dmpk expression in muscle

Source: United States Patent and Trademark Office (USPTO). Credit: Dyne Therapeutics Inc

A recently granted patent (Publication Number: US11911484B2) discloses a method for reducing the expression level of DMPK in muscle cells of a subject. The method involves administering a complex intravenously to the subject, comprising an anti-transferrin receptor antibody covalently linked to an oligonucleotide targeting a DMPK RNA. The oligonucleotide, 15-18 nucleotides in length, is designed to degrade the DMPK RNA via RNase H mediated degradation. The complex is configured to deliver the oligonucleotide into muscle cells, with the antibody binding to the transferrin receptor protein 1 (TfR1) of the subject.

Furthermore, the patent claims detail various aspects of the method, including the specific structure of the oligonucleotide, the protease-sensitive linker connecting it to the antibody, and the role of lysosomal and/or endosomal proteases in cleaving the linker. The method aims to reduce DMPK RNA levels by at least 50% in muscle cells, potentially rescuing splicing defects. The application of the complex is specified for skeletal, cardiac, or smooth muscle cells in human or cynomolgus subjects, particularly targeting disease-associated repeat sequences linked to myotonic dystrophy type 1 (DM1). The administration of the complex through intravenous infusion highlights the potential therapeutic implications of this method in addressing muscle-related disorders.

To know more about GlobalData’s detailed insights on Dyne Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies